GLP-1 Metabolic Therapy

Prescription GLP-1 receptor agonist therapy (injectables and oral medications) for medically-indicated weight loss and metabolic health improvement, supervised by senior consultant gastroenterologists with close monitoring for safety and efficacy.

GLP-1 (glucagon-like peptide-1) receptor agonists represent one of the most significant advances in obesity medicine in recent decades. Originally developed for type 2 diabetes management, medications such as semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda) have been shown in landmark trials to produce clinically meaningful and sustained weight loss by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. AliveoMedical's gastroenterologists are well-placed to prescribe and manage GLP-1 therapy given their specialist training in gastrointestinal and metabolic medicine. GLP-1 therapy at AliveoMedical is considered only after a thorough medical evaluation — BMI, body composition, medical history, and metabolic risk profile are all assessed before a prescription is issued. Both injectable formulations (weekly subcutaneous injection) and oral GLP-1 medications may be available depending on the patient's suitability and preference. Patients are counselled on expected side effects — most commonly nausea, digestive discomfort, or headache during the initial titration period — which are managed through dose adjustment and dietary guidance. The clinic emphasises that GLP-1 medications are not appropriate for everyone, and prescriptions are always clinically justified. Ongoing monitoring is integrated into the programme, with regular follow-ups to track weight, metabolic markers, and tolerability. GLP-1 therapy is typically used in combination with a structured nutrition plan and lifestyle guidance, rather than as a standalone intervention. This integrated, medically supervised approach distinguishes AliveoMedical's offering from unregulated or telehealth-only GLP-1 prescribers in Singapore.